ALMB-0166 has obtained approval from Australia for conducting the first-in-human clinical trial for the treatment of acute spinal cord injury.
ALMB-0166 is a First-in-Class humanized antibody against a novel target hemichannel composed of Cx43 membrane protein.
This orphan-drug designation will allow the Group to communicate with the U.S. FDA frequently and speed up the clinical development, registration
ALMB-0168 has obtained approval from Australia for conducting the first-in-human clinical trial for the treatment of bone cancer and cancer bone metastasis.
ALMB-0168 has been granted orphan-drug designation and rare pediatric disease designation by the U.S. FDA in 2019 for the
ALMB-0168 was granted Rare Pediatric Disease Designation by the U.S. FDA
ALMB-0168 was granted Orphan-Drug Designation by the U.S. FDA
AlaMab would welcome the opportunity to discuss possible investment or partnering opportunities.